ReviewFrontiers in pharmacology2021
Coordinated Contribution of NADPH Oxidase- and Mitochondria-Derived Reactive Oxygen Species in Metabolic Syndrome and Its Implication in Renal Dysfunction.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Effects and potential mechanisms of astragaloside IV in animal models of renal fibrosis: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- NADPH oxidases in immunometabolism and disease pathology: mechanistic networks, pollutant triggers, and therapeutic frontiers.Cellular & molecular immunology · 2026Review
- Therapeutic Modulation of Nitric Oxide Pathways to Address Insulin Resistance in Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026Review
- Exercise as a Molecular Therapeutic Strategy in Metabolic Syndrome: Integrating Cellular Signaling, Organ Crosstalk, and Clinical Translation-A Narrative Review.Current issues in molecular biology · 2026Review
- Metabolic Syndrome and Pancreatic Cancer: Linking Insulin Resistance, Inflammation, and Carcinogenesis.Diagnostics (Basel, Switzerland) · 2026Review
- Vitamin D and Metabolic Syndrome: Molecular Mechanisms and Clinical Implications: A Narrative Review.International journal of molecular sciences · 2026Review
- The Desert Duo: A Narrative Review on How Camel Milk and Date Fruits Combat Oxidative Stress and Enhance Metabolic Health.Antioxidants (Basel, Switzerland) · 2026Review
- Nature meets immunity: curcumin's role in modulating neutrophil extracellular traps.Inflammopharmacology · 2026Review
- The PVAT-MAMs Axis in Atherosclerosis: A Hypothesis-Driven Cross-Scale Conceptual Framework.International journal of molecular sciences · 2026Review
- Acrylamide Exposure Exacerbates Type 2 Diabetes-Induced Neurotoxicity: An Integrated Neurobehavioral and Molecular Investigation.Life (Basel, Switzerland) · 2026Article
- Effects of evolocumab combined with statin therapy on blood lipids, inflammatory factors, and endothelial function in patients with coronary heart disease.BMC cardiovascular disorders · 2026Article
- Metformin induces ferroptosis associated with lipidomic remodeling in AML.Blood advances · 2026Article
- Oxidative stress and endoplasmic reticulum stress in acute kidney injury: mechanistic crosstalk and therapeutic modulation.Frontiers in medicine · 2026Review
- Diuretic and Anti-hyperuricemic Effects of Geranyl Acetate in Rats.Current medicinal chemistry · 2026Article
- Micro Zhēngjiǎ as a reversible microstructural lesion network in diabetic myocardial fibrosis: mechanistic insights and therapeutic implications of Huoxue-Tongluo therapy.American journal of translational research · 2026Review
- The Role of MicroRNAs in Mitochondrial Homeostasis and their Involvement in the Pathogenesis of Obesity and Metabolic Syndrome: A Focus on MicroRNAs.Current medicinal chemistry · 2026Review
- GATA1 controls metadherin transcription to promote oxidative stress-induced podocyte injury.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Crosstalk between miRNAs and oxidative stress: implications for cancer pathogenesis and therapy.Functional & integrative genomics · 2025Review
- p75NTR Modulation by LM11A-31 Counteracts Oxidative Stress and Cholesterol Dysmetabolism in a Rotenone-Induced Cell Model of Parkinson's Disease.Neurochemical research · 2025Article
- Adipose-derived mesenchymal stromal cell secretome protects against kidney injury through induction of heme oxygenase 1 upregulationWorld journal of nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS), a complex of interrelated risk factors for cardiovascular disease and diabetes, is comprised of central obesity (increased waist circumference), hyperglycemia, dyslipidemia (high triglyceride blood levels, low high-density lipoprotein blood levels), and increased blood pressure. Oxidative stress, caused by the imbalance between pro-oxidant and endogenous antioxidant systems, is the primary pathological basis of MetS. The major sources of reactive oxygen species (ROS) associated with MetS are nicotinamide-adenine dinucleotide phosphate (NADPH) oxidases and mitochondria. In this review, we summarize the current knowledge regarding the generation of ROS from NADPH oxidases and mitochondria, discuss the NADPH oxidase- and mitochondria-derived ROS signaling and pathophysiological effects, and the interplay between these two major sources of ROS, which leads to chronic inflammation, adipocyte proliferation, insulin resistance, and other metabolic abnormalities. The mechanisms linking MetS and chronic kidney disease are not well known. The role of NADPH oxidases and mitochondria in renal injury in the setting of MetS, particularly the influence of the pyruvate dehydrogenase complex in oxidative stress, inflammation, and subsequent renal injury, is highlighted. Understanding the molecular mechanism(s) underlying MetS may lead to novel therapeutic approaches by targeting the pyruvate dehydrogenase complex in MetS and prevent its sequelae of chronic cardiovascular and renal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.